Literature DB >> 25896696

Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates.

Frédéric Lamoth1, Barbara D Alexander2.   

Abstract

The limited armamentarium of active and oral antifungal drugs against emerging non-Aspergillus molds is of particular concern. Current antifungal agents and the new orally available beta-1,3-d-glucan synthase inhibitor SCY-078 were tested in vitro against 135 clinical non-Aspergillus mold isolates. Akin to echinocandins, SCY-078 showed no or poor activity against Mucoromycotina and Fusarium spp. However, SCY-078 was highly active against Paecilomyces variotii and was the only compound displaying some activity against notoriously panresistant Scedosporium prolificans.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25896696      PMCID： PMC4468689          DOI： 10.1128/AAC.00234-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors.

Authors:  J Onishi; M Meinz; J Thompson; J Curotto; S Dreikorn; M Rosenbach; C Douglas; G Abruzzo; A Flattery; L Kong; A Cabello; F Vicente; F Pelaez; M T Diez; I Martin; G Bills; R Giacobbe; A Dombrowski; R Schwartz; S Morris; G Harris; A Tsipouras; K Wilson; M B Kurtz
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

Review 2.  Paecilomyces peritonitis: case report and review of the literature.

Authors:  K Wright; S Popli; V C Gandhi; J R Lentino; C V Reyes; D J Leehey
Journal:  Clin Nephrol       Date:  2003-04       Impact factor: 0.975

Review 3.  Neglected and emerging fungal infections: review of hyalohyphomycosis by Paecilomyces lilacinus focusing in disease burden, in vitro antifungal susceptibility and management.

Authors:  Paulo R Z Antas; Marcelly M S Brito; Érika Peixoto; Carlos G G Ponte; Cíntia M Borba
Journal:  Microbes Infect       Date:  2011-08-30       Impact factor: 2.700

4.  Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989-2006.

Authors:  Gregory A Lamaris; Georgios Chamilos; Russell E Lewis; Amar Safdar; Issam I Raad; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2006-11-09       Impact factor: 9.079

5.  Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model.

Authors:  Alexander J Lepak; Karen Marchillo; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2014-12-15       Impact factor: 5.191

Review 6.  Paecilomyces variotii fungemia in a patient with multiple myeloma: case report and literature review.

Authors:  Valery Salle; Emmanuelle Lecuyer; Taieb Chouaki; Francois Xavier Lescure; Amar Smail; Agnes Vaidie; Charles Dayen; Jean Luc Schmit; Jean Pierre Ducroix; Youcef Douadi
Journal:  J Infect       Date:  2005-10       Impact factor: 6.072

Review 7.  Changing epidemiology of systemic fungal infections.

Authors:  M Richardson; C Lass-Flörl
Journal:  Clin Microbiol Infect       Date:  2008-05       Impact factor: 8.067

8.  Susceptibility testing and molecular classification of Paecilomyces spp.

Authors:  Maria Victoria Castelli; Ana Alastruey-Izquierdo; Isabel Cuesta; Araceli Monzon; Emilia Mellado; Juan L Rodriguez-Tudela; Manuel Cuenca-Estrella
Journal:  Antimicrob Agents Chemother       Date:  2008-06-02       Impact factor: 5.191

Review 9.  Fusarium infections in immunocompromised patients.

Authors:  Marcio Nucci; Elias Anaissie
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132

10.  Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006.

Authors:  Benjamin J Park; Peter G Pappas; Kathleen A Wannemuehler; Barbara D Alexander; Elias J Anaissie; David R Andes; John W Baddley; Janice M Brown; Lisa M Brumble; Alison G Freifeld; Susan Hadley; Loreen Herwaldt; James I Ito; Carol A Kauffman; G Marshall Lyon; Kieren A Marr; Vicki A Morrison; Genovefa Papanicolaou; Thomas F Patterson; Trish M Perl; Mindy G Schuster; Randall Walker; John R Wingard; Thomas J Walsh; Dimitrios P Kontoyiannis
Journal:  Emerg Infect Dis       Date:  2011-10       Impact factor: 6.883
View more
  23 in total

Review 1.  Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies.

Authors:  David J Epstein; Susan K Seo; Janice M Brown; Genovefa A Papanicolaou
Journal:  J Antimicrob Chemother       Date:  2018-01-01       Impact factor: 5.790

2.  Penetration of Ibrexafungerp (Formerly SCY-078) at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model.

Authors:  Annie Lee; Brendan Prideaux; Matthew Zimmerman; Claire Carter; Stephen Barat; David Angulo; Véronique Dartois; David S Perlin; Yanan Zhao
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

Review 3.  New facets of antifungal therapy.

Authors:  Ya-Lin Chang; Shang-Jie Yu; Joseph Heitman; Melanie Wellington; Ying-Lien Chen
Journal:  Virulence       Date:  2016-11-07       Impact factor: 5.882

Review 4.  Exploiting mitochondria as targets for the development of new antifungals.

Authors:  Dongmei Li; Richard Calderone
Journal:  Virulence       Date:  2016-05-18       Impact factor: 5.882

Review 5.  Drugs in Clinical Development for Fungal Infections.

Authors:  Maria F Gonzalez-Lara; Jose Sifuentes-Osornio; Luis Ostrosky-Zeichner
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

6.  Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species.

Authors:  Michael A Pfaller; Shawn A Messer; Paul R Rhomberg; Katyna Borroto-Esoda; Mariana Castanheira
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

Review 7.  Targeting the fungal cell wall: current therapies and implications for development of alternative antifungal agents.

Authors:  Sahar Hasim; Jeffrey J Coleman
Journal:  Future Med Chem       Date:  2019-04-17       Impact factor: 3.808

8.  Invasive infections with Purpureocillium lilacinum: clinical characteristics and outcome of 101 cases from FungiScope® and the literature.

Authors:  Rosanne Sprute; Jon Salmanton-García; Ertan Sal; Xhorxha Malaj; Zdeněk Ráčil; Carlos Ruiz de Alegría Puig; Iker Falces-Romero; Aleksandra Barać; Guillaume Desoubeaux; Anupma Jyoti Kindo; Arthur J Morris; René Pelletier; Joerg Steinmann; George R Thompson; Oliver A Cornely; Danila Seidel; Jannik Stemler
Journal:  J Antimicrob Chemother       Date:  2021-05-12       Impact factor: 5.790

9.  In Vivo Efficacy of Olorofim against Systemic Scedosporiosis and Lomentosporiosis.

Authors:  S Seyedmousavi; Y C Chang; J H Youn; D Law; M Birch; J H Rex; K J Kwon-Chung
Journal:  Antimicrob Agents Chemother       Date:  2021-07-12       Impact factor: 5.191

Review 10.  New Horizons in Antifungal Therapy.

Authors:  Kaila M Pianalto; J Andrew Alspaugh
Journal:  J Fungi (Basel)       Date:  2016-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.